Phase 1/1b Multicenter Open-Label Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors

Go Back to All Clinical Trials

Phase 1/1b Multicenter Open-Label Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Krasg12d-mutant Solid Tumors
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Pathologically documented, locally advanced or metastatic solid tumor malignancy with KRASG12D-mutations identified through deoxyribonucleic acid (DNA) sequencing or polymerase chain reaction (PCR) test of an archival biopsy or circulating tumor DNA (ctDNA)
2. Participants must have received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
3. Participants should provide archival tumor samples collected within 5 years of C1D1

You may not be eligible for this study if the following are true:

1. Participant has primary CNS tumors
2. Participant has known or suspected leptomeningeal metastases or spinal cord compression
3. Participant with uncontrolled seizure disorder refractory to antiepileptics

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies